DMPA (DEPOT MEDROXYPROGESTERONE- ACETATE) INJECTION EFFECT ON LEPTIN LEVELS AND BODY MASS INDEX

Abstract

Introduction: MPA (depot medroxyprogesterone acetate) is an effective hormonal injectable contraceptive method, but some acceptors may experience side effects such as weight gain. This weight gain has been linked to increases in serum leptin levels.

Objectives: This study aims to analyze the relationship between leptin levels and Body Mass Index (BMI) in DMPA acceptors.

Methods: This study is an analytical observational study with a Prospective Cohort design. The sample consisted of 61 women with DMPA injection at the Health Center in Makassar. Statistical analysis used Kolmogorov-Smirnov and Wilcoxon test. DMPA acceptors (from the 6-12th month) was increase in BMI (obesity)

Results: Statistical analysis showed a significant relationship between the duration of DMPA use and BMI (P < 0.001). Serum leptin levels was increase after DMPA use (6-12th month). Statistical analysis showed a significant relationship between the duration of DMPA use and leptin levels (p < 0.001). A significant relationship was observed between BMI and leptin levels at the 12th month of DMPA use (p < 0.001), but not at the 6th month (p > 0.05).

Conclusions: The use of DMPA at the 12th month resulted in an increase in leptin levels and Body Mass Index (obesity)